Skip to main content

JAK/TYK2

RT @JulianSegan: Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at c

Julian Segan JulianSegan

3 weeks 1 day ago
Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking
RT @ericdeinmd: L06 #ACR22 ORAL Surveillance Updates!
Composite of all ischemic CV events and HF did NOT show difference

Eric Dein ericdeinmd

3 weeks 1 day ago
L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE
RT @DrCassySims: Does tofacitinib work better in patients with PsA and AS who smoke?

Abstract #1036 #ACR22 @RheumNow

Catherine Sims, MD DrCassySims

3 weeks 1 day ago
Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬
RT @JulianSegan: Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA,

Julian Segan JulianSegan

3 weeks 1 day ago
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action? @RheumNow ABST0297 #ACR22https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
RT @RichardPAConway: Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on

Richard Conway RichardPAConway

3 weeks 1 day ago
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5
RT @RichardPAConway: Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safe

Richard Conway RichardPAConway

3 weeks 1 day ago
Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp
RT @Janetbirdope: New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 m

Janet Pope Janetbirdope

3 weeks 1 day ago
New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML
RT @Janetbirdope: Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d

Janet Pope Janetbirdope

3 weeks 1 day ago
Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5
×